{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:55:04Z","timestamp":1787025304169,"version":"build-2736575974"},"reference-count":55,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:p>Pustular psoriasis is a distinct subset of psoriasis that presents with involvement of the skin in the form of sterile pustules along with systemic manifestations. Though it has been conventionally grouped under the umbrella of psoriasis, recent research has shed light on its pathogenetic mechanisms associated with the IL-36 pathway, which is distinct from conventional psoriasis. Pustular psoriasis in itself is a heterogeneous entity consisting of various subtypes, including generalised, localised, acute, and chronic forms. There is confusion regarding its current classification as entities like deficiency of IL-36 antagonist (DITRA) which are closely related to pustular psoriasis both in their pathogenetic mechanism and its clinical manifestations, are not included under pustular psoriasis. Entities like palmoplantar pustulosis, which presents with similar clinical features but is pathogenetically distinct from other forms of pustular psoriasis, are included under this condition. Management of pustular psoriasis depends upon its severity; while some of the localised variants can be managed with topical therapy alone, the generalised variants like Von Zumbusch disease and impetigo herpetiformis may need intensive care unit admission and tailor-made treatment protocols. The advent of newer biologics and better insight into the pathogenesis of pustular psoriasis has opened the way for newer therapies, including tumour necrosis factor-alpha inhibitors, interleukin-1 inhibitors, interleukin-17 inhibitors, and granulocyte monocyte apheresis. It continues to be an enigma whether pustular psoriasis is actually a variant of psoriasis or an entirely different disease entity, though we feel that it is an entirely different disease process.<\/jats:p>","DOI":"10.25259\/ijdvl_542_2022","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T08:35:11Z","timestamp":1685349311000},"page":"19-29","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pustular psoriasis: A distinct aetiopathogenic and clinical entity"],"prefix":"10.25259","volume":"90","author":[{"given":"Biju","family":"Vasudevan","sequence":"first","affiliation":[{"name":"Department of Dermatology, Armed Forces Medical College (AFMC), Wanowarie, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Armed Forces Medical College (AFMC), Wanowarie, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Armed Forces Medical College (AFMC), Wanowarie, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,5,28]]},"reference":[{"key":"10.25259\/IJDVL_542_2022\/ref-1","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/jdv.14949","article-title":"Generalized pustular psoriasis: a review and update on treatment","volume":"32","author":"Hoegler","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_542_2022\/ref-2","first-page":"669","article-title":"Generalized pustular psoriasis (Zumbusch): a French epidemiological survey","volume":"16","author":"Augey","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.16232","article-title":"Pustular psoriasis and related pustular skin diseases","volume":"178","author":"Bachelez","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/PTT.S180608","article-title":"Acrodermatitis continua of Hallopeau: clinical perspectives","volume":"9","author":"Smith","year":"2019","journal-title":"Psoriasis Targets Ther"},{"key":"10.25259\/IJDVL_542_2022\/ref-5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/09546631003636817","article-title":"Pustulosis palmoplantaris is a disease distinct from psoriasis","volume":"22","author":"de Waal","year":"2011","journal-title":"J Dermatol Treat"},{"key":"10.25259\/IJDVL_542_2022\/ref-7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_542_2022\/ref-8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/humu.22203","article-title":"Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis","volume":"34","author":"Farooq","year":"2013","journal-title":"Hum Mutat."},{"key":"10.25259\/IJDVL_542_2022\/ref-9","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J Invest Dermatol."},{"key":"10.25259\/IJDVL_542_2022\/ref-10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","article-title":"IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis","volume":"135","author":"Hussain","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"10.25259\/IJDVL_542_2022\/ref-11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25259\/IJDVL_1054_2021","article-title":"Correlation of IL36RN and CARD14 mutations with clinical manifestations and laboratory findings in patients with generalised pustular psoriasis","volume":"17","author":"Trai","year":"2022","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"key":"10.25259\/IJDVL_542_2022\/ref-12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00439-016-1750-y","article-title":"Mutations in IL36RN are associated with geographic tongue","volume":"136","author":"Liang","year":"2016","journal-title":"Hum Genet"},{"key":"10.25259\/IJDVL_542_2022\/ref-14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3892\/ijmm.2021.4951","article-title":"An update on genetic basis of generalized pustular psoriasis (Review)","volume":"47","author":"Zhou","year":"2021","journal-title":"Int J Mol Med"},{"key":"10.25259\/IJDVL_542_2022\/ref-15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ajhg.2014.04.005","article-title":"AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking","volume":"94","author":"Setta-Kaffetzi","year":"2014","journal-title":"Am J Hum Genet"},{"key":"10.25259\/IJDVL_542_2022\/ref-16","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jid.2016.06.618","article-title":"AP1S3 mutations cause skisn autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production","volume":"136","author":"Mahil","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jid.2018.07.025","article-title":"A Critical Role of the IL-1\u03b2\u2013IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis","volume":"139","author":"Cai","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/j.1365-2133.2010.09819.x","article-title":"Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis: Langerhans cells and IL-17 expression in PPP","volume":"163","author":"Hagforsen","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-22","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1038\/jid.2010.87","article-title":"Acrosyringium Is the Main Site of the Vesicle\/Pustule Formation in Palmoplantar Pustulosis","volume":"130","author":"Murakami","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1046\/j.1365-2133.2002.04640.x","article-title":"Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis","volume":"146","author":"Hagforsen","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/BTT.S199100","article-title":"Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau","volume":"13","author":"Smirnova","year":"2019","journal-title":"Biol Targets Ther"},{"key":"10.25259\/IJDVL_542_2022\/ref-25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/PTT.S126281","article-title":"Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management","volume":"7","author":"Haneke","year":"2017","journal-title":"Psoriasis Auckl NZ"},{"key":"10.25259\/IJDVL_542_2022\/ref-27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.anai.2017.09.077","article-title":"Acute generalized exanthematous pustulosis with multisystem manifestations: Pinpoint pustules and purulent lakes","volume":"120","author":"Rosen","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.25259\/IJDVL_542_2022\/ref-28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","article-title":"An update on generalized pustular psoriasis","volume":"15","author":"Gooderham","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.25259\/IJDVL_542_2022\/ref-29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40257-019-00492-0","article-title":"Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory Aspects","volume":"21","author":"Takeichi","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/ajd.12471","article-title":"Generalised pustular psoriasis and neutrophilic cholangitis: An infrequently reported association with excellent response to tumour necrosis factor inhibitors","volume":"58","author":"Rodr\u00edguez-Lomba","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/PTT.S98954","article-title":"Pustular psoriasis: pathophysiology and current treatment perspectives","volume":"6","author":"Mansouri","year":"2016","journal-title":"Psoriasis Targets Ther"},{"key":"10.25259\/IJDVL_542_2022\/ref-33","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000250117","article-title":"Impetigo Herpetiformis with Lowered Serum Level of Vitamin D and Its Diminished Intestinal Absorption","volume":"164","author":"Ott","year":"1982","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_542_2022\/ref-34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000250980","article-title":"Impetigo herpetiformis","volume":"155","author":"Bajaj","year":"1977","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_542_2022\/ref-35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/s0190-9622(89)70042-6","article-title":"Impetigo herpetiformis: A variant of pustular psoriasis or a separate entity?","volume":"20","author":"Lotem","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/00000372-198306000-00004","article-title":"Impetigo herpetiformis and pustular psoriasis during pregnancy","volume":"5","author":"Pierard","year":"1983","journal-title":"Am J Dermatopathol"},{"key":"10.25259\/IJDVL_542_2022\/ref-37","first-page":"106","article-title":"Characteristics of Acrodermatitis Continua of Hallopeau in Korea","volume":"56","author":"Yun","year":"2018","journal-title":"Korean J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-4632.2006.02473.x","article-title":"Acropustulosis repens","volume":"45","author":"Proenca","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/2319-7250.131828","article-title":"Parakeratosis pustulosa: A diagnostic conundrum","volume":"15","author":"Mahajan","year":"2014","journal-title":"Indian J Paediatr Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1468-3083.2002.00538.x","article-title":"The role of psychological factors in palmoplantar pustulosis","volume":"16","author":"S\u00e1ez-Rodr\u00edguez","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_542_2022\/ref-41","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/bjd.12223","article-title":"Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study: Comparison of palmoplantar plaque psoriasis and PPP","volume":"168","author":"Brunasso","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/ijd.13434","article-title":"Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996\u20132013","volume":"56","author":"Alniemi","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-44","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00403-002-0371-6","article-title":"Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity","volume":"295","author":"Umezawa","year":"2003","journal-title":"Arch Dermatol Res"},{"key":"10.25259\/IJDVL_542_2022\/ref-45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jaad.2011.01.032","article-title":"Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis Foundation","volume":"67","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40257-021-00653-0","article-title":"Clinical disease measures in generalized pustular psoriasis","volume":"23(Suppl 1)","author":"Burden","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-47","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","article-title":"Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP","volume":"45","author":"Fujita","year":"2018","journal-title":"J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/PTT.S98954","article-title":"Pustular psoriasis: pathophysiology and current treatment perspectives","volume":"6","author":"Benjegerdes","year":"2016","journal-title":"Psoriasis Auckl NZ"},{"key":"10.25259\/IJDVL_542_2022\/ref-49","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ad.2015.10.005","article-title":"Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations","volume":"107","author":"Carrascosa","year":"2016","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas Engl Ed"},{"key":"10.25259\/IJDVL_542_2022\/ref-50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2019.1682502","article-title":"Review of treatments for generalized pustular psoriasis","volume":"0","author":"Kearns","year":"2019","journal-title":"J Dermatol Treat"},{"key":"10.25259\/IJDVL_542_2022\/ref-51","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/1744666X.2020.1679625","article-title":"Anti IL-17 in psoriasis","volume":"15","author":"Ly","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.25259\/IJDVL_542_2022\/ref-52","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jdcr.2017.07.007","article-title":"Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities","volume":"3","author":"Jeon","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_542_2022\/ref-53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjd.13614","article-title":"Treatment of two patients with generalized pustular psoriasis with the interleukin-1\u03b2 inhibitor gevokizumab","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-54","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s13063-018-2914-y","article-title":"Treatment of pustular psoriasis with anakinra: a statistical analysis plan for stage 1 of an adaptive two-staged randomised placebo-controlled trial","volume":"19","author":"Cro","year":"2018","journal-title":"Trials"},{"key":"10.25259\/IJDVL_542_2022\/ref-55","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/1744-9987.12342","article-title":"Granulocyte and Monocyte Adsorption Apheresis for Generalized Pustular Psoriasis: Therapeutic Outcomes in Three Refractory Patients","volume":"19","author":"Fujisawa","year":"2015","journal-title":"Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther"},{"key":"10.25259\/IJDVL_542_2022\/ref-56","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2340\/00015555-2527","article-title":"Impetigo Herpetiformis Complicated with Intrauterine Growth Restriction Treated Successfully with Granulocyte and Monocyte Apheresis","volume":"97","author":"Saito-Sasaki","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_542_2022\/ref-57","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small Molecule IL-36\u03b3 Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis","volume":"9","author":"Todorovi\u0107","year":"2019","journal-title":"Sci Rep"},{"key":"10.25259\/IJDVL_542_2022\/ref-58","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of Spesolimab for Generalized Pustular Psoriasis. NEJM 2021","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_542_2022\/ref-60","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s13555-017-0207-0","article-title":"The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review","volume":"7","author":"Sanchez","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_542_2022\/ref-61","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4103\/JDRNTRUHS.JDRNTRUHS_109_17","article-title":"Pustular psoriasis\u2013Clinical study in a tertiary care center","volume":"7","author":"Chintagunta","year":"2018","journal-title":"Journal of Dr. NTR University of Health Sciences."},{"key":"10.25259\/IJDVL_542_2022\/ref-62","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1365-2133.2005.07071.x","article-title":"Measuring quality of life of patients with different clinical types of psoriasis using the SF-36","volume":"154","author":"Sampogna","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-63","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: ANALYSIS of 102 cases seen in a tertiary hospital in Johor, Malaysia","volume":"53","author":"Choon","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_542_2022\/ref-64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/PTT.S359011","article-title":"Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study","volume":"12","author":"L\u00f6fvendahl","year":"2022","journal-title":"Psoriasis (Auckl)."}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/pustular-psoriasis-a-distinct-aetiopathogenic-and-clinical-entity\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/pustular-psoriasis-a-distinct-aetiopathogenic-and-clinical-entity\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T15:10:12Z","timestamp":1703430612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/pustular-psoriasis-a-distinct-aetiopathogenic-and-clinical-entity\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,28]]},"references-count":55,"alternative-id":["10.25259\/IJDVL_542_2022"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_542_2022","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,28]]},"article-number":"19"}}